Press Room

Filter by year:
September 2, 2020

Amarisoft and Dali Wireless Collaborate to Deliver Open RAN Based 4G and 5G Solutions

Interoperability and co-marketing initiatives will bring new options for enterprises, and mobile network operators deploying in-building cellular solutions Menlo Park, California and Paris, France – February 11, 2020 – Dali Wireless, a global leader in wireless fronthaul innovation for virtual RAN, and Amarisoft, a pioneer in software centric 4G LTE and 5G NR technology and…

Read more
September 2, 2020

Dali Wireless Withdraws Attendance at Mobile World Congress (MWC) 2020

 Complying with recommendations from national and international health authorities, Dali has limited all non-essential travel   Menlo Park, California– February 10, 2020 – Dali Wireless, a global leader in wireless fronthaul innovation for virtual RAN has decided to withdraw its attendance from MWC Barcelona amid growing concerns surrounding the Novel Coronavirus (2019-nCoV). Dali’s top priority…

Read more
September 2, 2020

Brace Yourselves for a 5G Patents Punch-Up

As Chinese rivals ramp up their filings and shout loud about their portfolios, wireless and video technology patents specialist InterDigital has taken what looks like the bold step of unveiling its IPR (intellectual property rights) pricing structure in an effort to become a more transparent company. Taken in isolation, such a move is to be…

Read more
July 14, 2020

[Video] Maximizing Your Digital Publishing Strategy: A Virtual Roundtable

GTxcel recently had the pleasure of hosting a virtual discussion panel for the City & Regional Magazine Association to discuss best practices for digital publishing. Sponsor City & Regional Magazine Association HostChris Collett, Director of Digital Strategy at GTxcel Co-Hosts Dan Fitek, Director of Product Development at GTxcelLeah Miranda, Senior Manager, Email Marketing at Campaign…

Read more
July 14, 2020

Predicting Reader Behavior with Publisher Analytics

Predicting changes in reader behavior is the key to a successful audience development strategy. Sudden shifts in audience behavior, like those caused by the recent COVID-19 pandemic, can be unpredictable, dramatic and affect all aspects of your publishing ecosystem. More predictable changes, such as those based on technology or infrastructure improvements, typically occur gradually and…

Read more
July 13, 2020

Should You Be Testing New Subscription Models?

Because digital subscriptions are flexible and can be quickly modified, there are always opportunities to test and innovate with different subscriber access models. For print-only subscriptions, the relationship between payment and access has always been straightforward: the customer provides payment (in the form of money or information), and your content gets delivered to them. In the…

Read more
July 13, 2020

Publishers Need Continuity During Print Channel Disruptions

When conventional distribution channels become disrupted, Turnstyle can provide continuity, delivering your content, and providing peace of mind. There’s little doubt that the COVID-19 pandemic has changed the digital publishing landscape. Supply chain disruptions and reduced ad spending have forced publishers to take a hard look at their short and long-term digital strategies. As the…

Read more
July 1, 2020

ProterixBio licenses COVID-19 serology test from Massachusetts General Hospital

Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University which is a joint venture of Harvard University, Massachusetts…

Read more
June 25, 2020

Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002 at Digestive Disease Week 2020 Virtual Scientific Program

Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator – Dose-dependent reduction in circulating lymphocytes –– Rapid lymphocyte recovery after cessation of dosing –– Phase 2 study in ulcerative colitis patients in 4Q 2020 – ENCINITAS, California and Cambridge, United Kingdom, June 23, 2020 – Oppilan Pharma, Ltd., a clinical-stage biopharmaceutical company focused on developing…

Read more